Non-surgical Periodontal Treatment and Periostin Levels

Sponsor
Mustafa Kemal University (Other)
Overall Status
Completed
CT.gov ID
NCT05535049
Collaborator
(none)
48
1
2
23
2.1

Study Details

Study Description

Brief Summary

The aim of this study was to investigate the effect of non-surgical periodontal treatment on the periostin levels in serum and gingival crevicular fluid (GCF) in patients with periodontitis.

There were two study groups consisting of individuals who had periodontitis and those who were healthy, with 24 individuals in each group. Periostin levels were assessed at baseline, at the 24th h, 48th h, 14th day 1st month, 3rd month after non-surgical periodontal treatment in serum and GCF samples. In parallel, interleukin 1 beta and fibroblast growth factor levels were measured.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Non-surgical periodontal treatment
N/A

Detailed Description

The observational prospective study was designed to characterize periostin changes over time after non-surgical periodontal treatment in serum and GCF in the Department of Periodontology in the Faculty of Dentistry at Hatay Mustafa Kemal University, Hatay, Turkey. The study protocol was approved by the Ethics Committee for the Use of Human Subjects in Research of Hatay Mustafa Kemal University (Protocol No: 2019/118). The study was carried out in accordance with the tenets of the Declaration of Helsinki and conducted in CONSORT guidelines (Schulz, Altman, & Moher, 2010). This study project was financially supported by Hatay Mustafa Kemal University Scientific Research Projects Coordinator (19M051).

Individuals were included in the study from December 2019 through August 2021. Written informed consent was obtained from each participant before the clinical periodontal examination.

Study Population

Forty-eight adult individuals were enrolled in the study. Participants were recruited into 2 sex matched groups with 24 participants in each: periodontally healthy (PH) and periodontitis (P) groups. In accordance with the demographic variables of the patients included in the P group, the patients in the PH groups were included.

Periodontal Parameters

Periodontal clinical parameters were recorded by a single calibrated examiner (k =0.95) (author AS). Intra-examiner agreement was determined for CAL. The intra-examiner reproducibility was determined through repeated examinations of 10 subjects with a one-hour interval. Clinical periodontal measurements were assessed using the following periodontal measurements for periodontal diagnosis in both groups and also at the 1st month, 3rd month after non-surgical periodontal treatment in the periodontitis group.

The measurements were performed using a Williams periodontal probe (Hu-Friedy, Chicago, IL, USA) and included probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI) (Silness & Loe, 1964), gingival index (GI) (Loe & Silness, 1963), and percentage bleeding on probing (BOP) (Ainamo & Bay, 1975) at six sites per tooth (mesio-buccal, buccal, disto-buccal, mesio-lingual, lingual and disto-lingual) on each tooth.

Diagnosis of periodontal diseases and conditions was made according to the radiographic and clinical diagnostic criteria proposed by the 2017 World Workshop on Classification of Periodontal and Peri-implant Diseases and Conditions (Caton et al., 2018). Individuals with BOP < 10% without attachment loss and radiographic bone loss were considered to have periodontal health (Tonetti & Sanz, 2019). The criteria for periodontitis included patients with CAL ≥ 5 mm in two or more interproximal sites and PPD ≥ 6 mm in one or more interproximal sites. Only stage III-IV (severe) periodontitis was included in the present study (Tonetti, Greenwell, & Kornman, 2018).

Periodontal Intervention

Periodontitis patients were treated by one-stage full-mouth disinfection. Full-mouth disinfection included full-mouth scaling and root planning procedures within 24 h in two sessions. Each session was practiced for 60 min on two consecutive days. Subgingival irrigation and tongue brushing were made with 1% CHX gel for 1 min. Mouthwashes with 0.12% CHX were performed for 30 s at the beginning and at the end of each session and twice a day for 2 weeks (Quirynen et al., 1995).

Collection of GCF Samples

GCF samples were collected following 8 hours of night fasting and one week after clinical periodontal measurements at baseline in two groups and then at the the 24th h, 48th h, 14th day 1st month, 3rd month after non-surgical periodontal treatment (Akalin, Baltacioglu, Alver, & Karabulut, 2007). The samples were collected from the teeth side with PPDs ≥6 mm, and BOP positive in patients with periodontitis. Six GCF samples were taken per participant. Samples were collected from a mesial and a distal site on each of three teeth (incisors, premolars, and molars). Saliva contamination was prevented by isolation with cotton rolls and gently air-drying the sampling area. Samples contaminated with saliva or blood were not included. Plaque was gently removed from the sampling area by the periodontal curette. The samples were collected within 30 seconds with standardized paper strips (Periopaper; Oraflow Inc., Plainview, NY) by the orifice method.(Rudin, Overdiek, & Rateitschak, 1970) The volumes were measured on a pre-calibrated electronic gingival fluid measuring device (Oraflow Inc., Plainview, NY)|| (Chapple, Landini, Griffiths, Patel, & Ward, 1999). The values of the electronic device were referenced to a standard curve and converted to an actual volume (µl). All of the Periopaper strips were pooled in plastic Eppendorf microcentrifuge tubes. They were stored at -80 °C until the biochemical analysis.

All samples were thawed and 375 μl of phosphate buffered saline (pH:7.00, 10 mM Na2PO4, 137 mM NaCl, and 2.7 mM KCl) was added into the eppendorf tubes containing the sample strips. Subsequently, samples were eluted for 30 minutes at room temperature and (Chapple et al., 1997) centrifuged at 11000×g for 15 min at 4 °C. The measurement of periostin, IL-1β, and FGF levels were assayed.

Collection of Serum Samples

Peripheral venous blood samples were taken from the patients. The serum was separated from the cells by centrifugation at 2000 rpm for 10 min, after which it was stored at -80°C, until the biochemical analysis was performed.

Laboratory Analyses

Periostin, IL-1β, and FGF levels were measured by the enzyme-linked immunosorbent assay (ELISA) using commercially available kits at 450 nm wavelength in ELISA Reader (Thermo Fisher Scientific Multiscan Go-Finland).

Measurement of periostin levels in GCF samples

Periostin levels were measured by ELABSCIENCE Human POSTN/OSF-2 (Kit Cat No: E-EL-H6113). The assay ranges for the periostin were 3.13-200 ng/ml; sensitivity, 1.88 ng/ml, intra and inter assay coefficients of variance (CV%) were < 10%.

Measurement of IL-1β levels in GCF samples

IL-1β levels were measured by ELABSCIENCE Human IL-1β (Kit Cat No: E-EL-H0149). The assay ranges for the IL-1β were 7.81-500 pg/ml; sensitivity, 4.69 pg/ml, intra and inter assay coefficients of variance (CV%) were < 10%.

Measurement of FGF levels in GCF samples

FGF levels were measured by ELABSCIENCE Human FGF21 (Kit Cat No: E-EL-H0074). The assay ranges for the FGF were 31.25-2000 pg/ml; sensitivity, 18.75 pg/ml, intra and inter assay coefficients of variance (CV%) were < 10%.

Statistical Analysis

The normality of the distribution of continuous variables was tested by the Shapiro-Wilk test. Descriptive statistics were presented as mean and standard deviation (mean±sd) for parametric distributed variables and median (interquartile range) for the non-parametric distributed variables.

The chi-square test was used to analyze the associations between categorical variables. The Student t-test for normally distributed numerical variables and Mann Whitney u test for non-normally distributed numerical variables were performed to compare 2 independent groups for numerical data. Freidman test was performed for different time points with non-parametric variables. Dunn multiple comparison tests were performed for post hoc pairwise multiple comparison analyses.

Statistical analysis was performed with SPSS for Windows version 24.0 and P value <0.05 was accepted as statistically significant.

Study Design

Study Type:
Interventional
Actual Enrollment :
48 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
The Effect of Non-surgical Periodontal Treatment on Serum and Gingival Crevicular Fluid Periostin Levels
Actual Study Start Date :
Dec 1, 2019
Actual Primary Completion Date :
Aug 1, 2021
Actual Study Completion Date :
Nov 1, 2021

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Periodontally healthy group

24 participants were included in this group.

Active Comparator: Periodontitis group

24 participants were included in this group.

Procedure: Non-surgical periodontal treatment
Full month non-surgical periodontal treatment procedure was applied to the periodontitis group.

Outcome Measures

Primary Outcome Measures

  1. Evaluation of Periostin levels in non-surgical periodontal treatment [0-3 month]

    The effect of non-surgical periodontal treatment on serum and gingival crevicular fluid periostin levels

Secondary Outcome Measures

  1. Evaluation of IL-1B and FGF levels in non-surgical periodontal treatment [0-3 month]

    The effect of non-surgical periodontal treatment on serum and gingival crevicular fluid cytokines levels

Eligibility Criteria

Criteria

Ages Eligible for Study:
24 Years to 58 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • individuals who had never smoked;

  • individuals who had no history of periodontal treatment in the past 6 months;

  • individuals who had had no antibiotic therapy in the past 3 months;

  • individuals who had more than 18 teeth.

Exclusion Criteria:
  • individuals who were pregnant;

  • individuals were current or former smokers;

  • individuals who had any self-reported systemic condition or disease, which are confounding factors e.g. AIDS, rheumatoid arthritis, cardiovascular diseases, diabetes.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mustafa Kemal University Hatay Turkey 31000

Sponsors and Collaborators

  • Mustafa Kemal University

Investigators

  • Principal Investigator: Aysegul Sari, PhD, Hatay Mustafa Kemal University Dental Faculty
  • Study Chair: Oguzhan Ozcan, Prof, Hatay Mustafa Kemal University Medical Faculty
  • Study Director: Alpdogan Kantarci, Prof, Boston University Goldman School of Dental Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Aysegul SARI, Scientific research projects, Mustafa Kemal University
ClinicalTrials.gov Identifier:
NCT05535049
Other Study ID Numbers:
  • 2019/118
First Posted:
Sep 10, 2022
Last Update Posted:
Sep 10, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Aysegul SARI, Scientific research projects, Mustafa Kemal University

Study Results

No Results Posted as of Sep 10, 2022